| Literature DB >> 35059141 |
Young-Sup Lee1, Seungwoo Son2, Jaeyoung Heo1, Donghyun Shin2.
Abstract
Although there have been many genome-wide association studies (GWAS) and selective sweep analyses to understand pig genomic regions related to growth performance, these methods considered only the gene effect and selection signal, respectively. In this study, we suggest the cross-population phenotype associated variant (XP-PAV) analysis as a novel method to determine the genomic variants with different effects between the two populations. XP-PAV analysis could reveal the differential genetic variants between the two populations by considering the gene effect and selection signal simultaneously. In this study, we used daily weight gain (DWG) and back fat thickness (BF) as phenotypes and the Landrace and Yorkshire populations were used for XP-PAV analysis. The main aim was to reveal the differential selection by considering the gene effect between Landrace and Yorkshire pigs. In the gene ontology analysis of XP-PAV results, differential selective genes in DWG analysis were involved in the regulation of interleukin-2 production and cell cycle G2/M transition. The protein modification and glycerophospholipid biosynthetic processes were the most enriched terms in the BF analysis. Therefore, we could identify genetic differences for immune and several metabolic pathways between Landrace and Yorkshire breeds using the XP-PAV analysis. In this study, we expect that XP-PAV analysis will play a role in determining useful selective variants with gene effects and provide a new interpretation of the genetic differences between the two populations.Entities:
Keywords: Cross-population phenotype associated variant (XP-PAV); back fat thickness; daily weight gain; differential genomic variant; t-test
Year: 2021 PMID: 35059141 PMCID: PMC8765246 DOI: 10.1080/19768354.2021.2006310
Source DB: PubMed Journal: Anim Cells Syst (Seoul) ISSN: 1976-8354 Impact factor: 1.815
Figure 1.(a) Principal Component Analysis (PCA) plot of Landrace (LL) and Yorkshire (YY) pigs. By PC1, two breeds were distinct. (b, c, d, e) The boxplot according to sex (b, c) and parity (d, e) in LL and YY, respectively. The boxplot of sex and parity did not show a significant difference between LL and YY pigs, but difference in marker effects in genome-wide association (GWA) test was observed.
Figure 3.The mean effect plot of Landrace (LL; orange) and YY (Yorkshire; red). The gene regions with lowest p-value were presented in blue lines. (a) In daily weight gain (DWG), the regulator of nonsense mediated mRNA decay (UPF2) was highly significant. (b) In back fat (BF), GRB2 associated binding protein 2 (GAB2) was the most significant.
Figure 2.(a) Manhattan plot of XP-PAV results of –log10(p-value). (b, c) The Venn diagram of results of the number of significant variants in genome-wide association studies (GWAS) and cross-population phenotype associated variant (XP-PAV). The significant variants’ p-values were Bonferroni p-value <0.01 in GWAS daily weight gain (DWG), p-value <0.001 in GWAS back fat thickness (BF), and p-value <0.05 in XP-PVA DWG and BF, respectively.
The significant detected single nucleotide polymorphisms (SNPs) (top 5 in each phenotype) and encompassing genes in cross-population phenotype-associated variant (XP-PAV)
| CHR | SNP | Position | Genes | Phenotypes | |
|---|---|---|---|---|---|
| 13 | ASGA0059801 | 203,697,839 | 3.46E-05 | BF | |
| 9 | ALGA0051430 | 12,691,365 | 6.96E-05 | BF | |
| 16 | ALGA0090605 | 48,859,252 | 7.99E-05 | BF | |
| 6 | MARC0018856 | 65,196,951 | 8.17E-05 | BF | |
| 16 | ASGA0073290 | 48,791,895 | 8.17E-05 | BF | |
| 13 | ALGA0073375 | 198,378,920 | 3.12E-05 | DWG | |
| 10 | ASGA0102557 | 59,920,758 | 5.48E-05 | DWG | |
| 4 | ALGA0025364 | 67,304,102 | 7.90E-05 | DWG | |
| 10 | ALGA0059370 | 60,133,955 | 8.02E-05 | DWG | |
| 13 | ALGA0071935 | 137,841,013 | 8.25E-05 | DWG |
Gene Ontology (GO) of differential genes in daily weight gain (DWG) (cross-population phenotype-associated variant; XP-PAV p-value <0.05). The most enriched terms were regulation of interleukin-2 production and G2/M cell cycle.
| Term | Count | Genes | Fold enrichment | |
|---|---|---|---|---|
| GO:0032743∼positive regulation of interleukin-2 production | 5 | 0.000 | 14.2 | |
| GO:1902882∼regulation of response to oxidative stress | 6 | 0.000 | 9.0 | |
| GO:0044839∼cell cycle G2/M phase transition | 7 | 0.001 | 6.0 | |
| GO:0032663∼regulation of interleukin-2 production | 5 | 0.002 | 9.0 | |
| GO:0050801∼ion homeostasis | 17 | 0.002 | 2.4 | |
| GO:0000086∼G2/M transition of mitotic cell cycle | 6 | 0.003 | 6.2 | |
| GO:1900407∼regulation of cellular response to oxidative stress | 5 | 0.003 | 8.4 | |
| GO:0098655∼cation transmembrane transport | 14 | 0.003 | 2.6 | |
| GO:0044770∼cell cycle phase transition | 11 | 0.003 | 3.1 | |
| GO:0032623∼interleukin-2 production | 5 | 0.003 | 7.9 | |
| GO:0045785∼positive regulation of cell adhesion | 11 | 0.004 | 3.0 |
Gene Ontology (GO) of differential genes in back fat thickness (BF) (cross-population phenotype-associated variant; XP-PAV p-value <0.05). The most enriched terms were the protein modification and glycerolipid biosynthetic processes.
| Term | Count | Genes | Fold Enrichment | |
|---|---|---|---|---|
| GO:0046474∼glycerophospholipid biosynthetic process | 6 | 0.001 | ALOX15, PIGU, PIGK, ATM, SLC27A1, CRLS1 | 7.6 |
| GO:0036211∼protein modification crprocess | 47 | 0.001 | TSSK1B, ALOX15, ARFGEF1, UBE2 K, NEK10, SATB1, NAA16, FBXW7, MEF2C, ITGA5, STT3B, PBLD, DAB2, MAST1, PRKAR2A, KAT7, SLC27A1, ASXL1, RNF13, P4HA1, PIGU, FBXO21, CAMK2D, MEF2A, PLCB1, WWTR1, TBC1D7, JMJD1C, PSAP, ZDHHC1, STOX1, RNF144B, ATM, CCL21, ZER1, KAT14, UBQLN1, ATG7, TNFRSF19, PIGK, KLHL29, GCLC, NEDD4L, KLHL1, USP54, ENSA, HLTF | 1.6 |
| GO:0006464∼cellular protein modification process | 47 | 0.001 | TSSK1B, ALOX15, ARFGEF1, UBE2 K, NEK10, SATB1, NAA16, FBXW7, MEF2C, ITGA5, STT3B, PBLD, DAB2, MAST1, PRKAR2A, KAT7, SLC27A1, ASXL1, RNF13, P4HA1, PIGU, FBXO21, CAMK2D, MEF2A, PLCB1, WWTR1, TBC1D7, JMJD1C, PSAP, ZDHHC1, STOX1, RNF144B, ATM, CCL21, ZER1, KAT14, UBQLN1, ATG7, TNFRSF19, PIGK, KLHL29, GCLC, NEDD4L, KLHL1, USP54, ENSA, HLTF | 1.6 |
| GO:0007010∼cytoskeleton organization | 22 | 0.002 | ALOX15, PHACTR1, TACC2, MAP2, MEF2A, DST, MYPN, ARHGAP10, ARFGEF1, DOCK1, CCL21, AP1AR, EPB41L2, CDC42EP4, MEF2C, CDC14A, VPS54, KIF23, TPPP3, MAST1, ARHGAP26, SVIL | 2.1 |
| GO:0032446∼protein modification by small protein conjugation | 15 | 0.002 | RNF13, FBXO21, WWTR1, TBC1D7, RNF144B, UBE2 K, FBXW7, ZER1, UBQLN1, ATG7, NEDD4L, KLHL29, GCLC, KLHL1, HLTF | 2.5 |
| GO:0070647∼protein modification by small protein conjugation or removal | 17 | 0.002 | ASXL1, RNF13, FBXO21, WWTR1, TBC1D7, RNF144B, UBE2 K, FBXW7, ZER1, UBQLN1, ATG7, NEDD4L, KLHL29, GCLC, KLHL1, USP54, HLTF | 2.3 |
| GO:0071277∼cellular response to calcium ion | 4 | 0.003 | CARF, ALOX15, MEF2C, MEF2A | 13.5 |
| GO:0016567∼protein ubiquitination | 14 | 0.003 | RNF13, FBXO21, WWTR1, TBC1D7, RNF144B, UBE2 K, FBXW7, ZER1, UBQLN1, NEDD4L, KLHL29, GCLC, KLHL1, HLTF | 2.6 |
| GO:0045017∼glycerolipid biosynthetic process | 6 | 0.004 | ALOX15, PIGU, PIGK, ATM, SLC27A1, CRLS1 | 5.8 |
| GO:0008654∼phospholipid biosynthetic process | 6 | 0.004 | ALOX15, PIGU, PIGK, ATM, SLC27A1, CRLS1 | 5.7 |
| GO:0006650∼glycerophospholipid metabolic process | 7 | 0.005 | ALOX15, PIGU, PIGK, ATM, PIK3CD, SLC27A1, CRLS1 | 4.5 |